Northwest Biotherapeutics Presents Personalized Cancer Vaccine Approach at NHS Conference
News related to:Northwest Biotherapeutics · 2 min read
BETHESDA, Md., Oct. 6, 2026 /CourierPR/ -- Northwest Biotherapeutics, a biotechnology company focused on developing personalized immune therapies, will present groundbreaking research at the UK National Health Service (NHS) CancerCare Oncology Conference. UK time.
Dr. Bosch will delve into the evolving landscape of cancer vaccines, emphasizing the necessity of personalized treatments. He will discuss the unique capabilities of dendritic cell (DC) based cancer vaccines, such as the company’s DCVax® technology, and share clinical trial results. The presentation will also explore potential combination treatments and related matters.
Northwest Biotherapeutics has a robust platform technology for DCVax® dendritic cell-based vaccines. The company’s lead program, DCVax®-L treatment for glioblastoma (GBM), is the most aggressive and lethal form of primary brain cancer. The GBM program has completed a 331-patient Phase III trial, with results presented in scientific meetings, published in JAMA Oncology, and submitted for commercial approval in the UK. The MAA is currently undergoing review.
Additionally, the company has developed DCVax®-Direct for inoperable solid tumor cancers, which has completed a 40-patient Phase I trial and plans to pursue Phase II trials this year. The company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
The presentation will highlight the company’s commitment to advancing personalized cancer treatments, aiming to provide more effective therapies with fewer toxicities compared to traditional chemotherapies. The findings and insights shared during the keynote will be of significant interest to NHS leaders, clinicians, and other healthcare professionals attending the annual conference.
Northwest Biotherapeutics continues to navigate the complexities of regulatory processes and remains dedicated to bringing innovative treatments to patients. The company’s forward-looking statements, including those regarding its products, are subject to various risks and uncertainties, as detailed in its Securities and Exchange Commission filings.
The CancerCare Conference brings together NHS leaders and clinicians, cancer alliances, and other healthcare professionals from across the UK to discuss developments in cancer care, innovation, and emerging treatments. The event serves as a platform for sharing knowledge and fostering collaboration among key stakeholders in the field of oncology.
Northwest Biotherapeutics’ presentation is expected to contribute valuable insights into the future of cancer immunotherapy, particularly in the context of personalized, multi-target approaches. Attendees will have the opportunity to engage with Dr. Bosch and learn about the latest advancements in the company’s research and development efforts.